Takeda Pharmaceutical Company Limited (NYSE: TAK) announced that the U.S. Food and Drug Administration (FDA) has approved MIMRYLO (rusfertide) for treating erythrocytosis in adults with polycythemia vera.

The approval marks a significant milestone for the first-in-class hepcidin mimetic, which targets the underlying mechanism of iron dysregulation in this chronic blood cancer. The regulatory decision triggers $275 million in immediate payments to development partner Protagonist Therapeutics Inc. (NASDAQ: PTGX).

Clinical Efficacy and Safety

The regulatory decision was supported by data from the global randomized Phase 3 VERIFY study, which included 293 patients. During weeks 20-32 of the trial, 76.9% of patients achieved a clinical response, defined as the absence of phlebotomy eligibility.

MIMRYLO demonstrated efficacy in maintaining hematocrit control below 45%, the primary treatment goal for polycythemia vera. The therapy also reduced the need for phlebotomy and improved fatigue scores as measured by the PROMIS Fatigue Short Form 8a. An open-label extension of the VERIFY trial remains ongoing, with further findings planned for upcoming medical conferences.

Safety data indicated that MIMRYLO was generally well-tolerated through 52 weeks of treatment. The most common adverse reactions were injection site reactions (56%) and anemia (16%).

Commercialization and Financial Impact

Takeda will commercialize MIMRYLO under a worldwide license agreement entered into in 2024 with Protagonist Therapeutics. Protagonist discovered rusfertide (PTG-300) and led development through Phase 3, with Takeda assuming responsibility for NDA submission and commercialization following Protagonist’s opt-out election in April 2026.

The FDA approval triggers $275 million in payments to Protagonist, consisting of a $200 million opt-out fee and a separate $75 million approval milestone. Protagonist is eligible to receive up to an additional $875 million in total potential milestone payments, as well as tiered royalties ranging from 14% to 29% on worldwide net sales.

Takeda stated that this approval does not result in any changes to its consolidated financial forecast for the fiscal year ending March 31, 2027 (FY26). The company is working with regulators outside the U.S. to potentially bring MIMRYLO to more patients worldwide.

Market Context

Polycythemia vera affects approximately 90,000 people in the U.S. Current standard-of-care treatments, including phlebotomy and cytoreductive therapies, leave an estimated 78% of patients with uncontrolled hematocrit levels. Uncontrolled hematocrit increases blood viscosity and raises the risk of life-threatening thrombotic events, including stroke and pulmonary embolism.

Andrew T. Kuykendall, M.D., lead investigator for the VERIFY study, noted that current treatments leave a significant gap for many patients. He stated that the consistency of the VERIFY data provides confidence in MIMRYLO’s potential to advance treatment practices.

Julie Kim, President and Chief Executive Officer of Takeda, described the approval as an inflection point for delivering three new medicines that could drive future growth.

What the Numbers Show

The high incidence of injection site reactions (56%) compared to systemic adverse events like anemia (16%) suggests that tolerability issues are primarily localized rather than systemic. This profile may influence patient adherence strategies, as localized reactions are often manageable with topical interventions, unlike systemic side effects that may require dose modifications or discontinuation.

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 (NT1) in adults. The approval establishes ORZEYFUL as the only medicine in Japan indicated to treat the disease holistically rather than managing individual symptoms.

The Japanese MHLW approval marks the third major regulatory milestone for ORZEYFUL globally. The drug is already approved for NT1 treatment in China and the United States. In the US, the controlled substance classification for ORZEYFUL remains under review by the Drug Enforcement Administration (DEA).

Clinical Basis and Mechanism

ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist discovered by Takeda’s laboratories in Japan. It selectively stimulates OX2R to restore signaling and address the underlying orexin deficiency associated with NT1. By activating these receptors, the drug promotes wakefulness and reduces abnormal rapid eye movement (REM)-sleep like phenomena, including cataplexy.

The approval relies on data from global Phase 3 studies, FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002). These trials demonstrated statistically significant improvements across the full range of NT1 symptoms assessed, including excessive daytime sleepiness and cataplexy, compared to placebo. The safety profile was consistent across studies, with common adverse events including insomnia, urinary urgency, urinary frequency, and excessive saliva.

Product Details in Japan

Takeda is proceeding with launch preparations to make ORZEYFUL available as quickly as possible. The product will be marketed as Orzeyful Tablet in strengths of 0.5mg, 1mg, and 2mg.

Strategic Context

Julie Kim, president and chief executive officer of Takeda, stated that the discovery represents Japan-originated science impacting patients globally. She described ORZEYFUL as the first validation of Takeda’s broader orexin strategy.

Asuka Miyabashira, president of the Japan Pharma Business Unit at Takeda, credited scientists in Japan for targeting the underlying orexin deficiency. Takeda continues to investigate other oral orexin agonists, including TAK-360 for NT1, narcolepsy type 2, and idiopathic hypersomnia, as well as TAK-495.

What the Numbers Show

The simultaneous availability of ORZEYFUL in three major markets—Japan, China, and the US—highlights the efficiency of Takeda’s global development pipeline for this asset. While the US market faces a regulatory delay regarding DEA classification, the immediate commercial potential in Japan and China allows Takeda to begin capturing revenue from this first-in-class therapy without waiting for full global harmonization.